Physician profile
Isabel Puri
NPI 1033154182
$6,520.43
in general payments reported to CMS, 2019-2025
23 companies · $691 in 2025
The $691 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,860 · 2020: $807 · 2021: $930 · 2022: $893 · 2023: $646 · 2024: $694 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,976.68 | 2021-2025 | |
| Allergan, INC. | $832.86 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $783.18 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $491.70 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $447.26 | 2021-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $332.76 | 2019-2023 | Invega, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $227.45 | 2019-2023 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $174.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.48 | 2019-2020 | |
| Bausch Health US, LLC | $142.78 | 2019-2024 | Aplenzin |
| Avanir Pharmaceuticals, INC. | $135.20 | 2019 | |
| Corium, LLC | $134.05 | 2022-2024 | Azstarys |
| Neos Therapeutics, LP | $130.04 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $119.50 | 2019-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $97.02 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $85.12 | 2019-2020 | |
| Adlon Therapeutics L.P. | $66.96 | 2020-2021 | |
| Alkermes, INC. | $61.20 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $43.79 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.54 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $23.47 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.63 | 2023 | Quviviq |
| Tris Pharma INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.